230 Users Online
Fc Fusion Protein Market Segmented By Application such as In vitro, Immunohistochemistry, Flow Cytometry, Binding assays, Microarray technologies, In vivo and Bio-therapeutic Drugs
Fc-Fusion Proteins also called as Fc chimeric proteins or Fc-Ig based chimeric fusion protein and also Fc-tag protein. The Fc-Fusion Protein is a composition Fc domain of IgG which is genetically linked to a peptide/protein of interest. Fc-Fusion Protein has gained importance in the in vivo and in-vitro research.
The Fc-fusion proteins can range single peptides, a ligand activating upon binding to a cell receptor, signaling molecules, an extracellular domain of the receptor and also as a bait protein which identifies the binding partners in a protein microarray. One of the important features of the Fc-Fusion Proteins in vivo is that it can prolong the plasma half-life of the desired protein.
This feature of the Fc-Fusion Protein improves the therapeutic efficacy of the biological drugs. Fc-Fusion Proteins are now routinely used in the non-clinical applications like immunohistochemistry, protein arrays, and flow cytometry.In these applications, the FC region is stable and folds independently to which other different types of proteins can get attached and remain functional.
There are many Fc-fusion proteins in clinical trials, and many are there at different stages of pre-clinical development.Fc-Fusion proteins and monoclonal antibodies collectively account for a total of 43% among the all therapeutic proteins market. Many Fc-Fusion proteins are still in pipeline which indicates that the market of Fc-Fusion Proteins is likely to rise in the forecast period 2016-2024.
From studies and global sales, the most successful Fc-fusion protein is Etanercept, which exceeded the utmost successful therapeutic antibody Bevacizumab. The market for Fc-fusion protein market is analogous to the biologics, pharmaceuticals and biotechnology market.
The Fc-fusion protein market is most likely to increase in the forecast period 2016-2024. The restraining factors in the Fc-fusion protein market may be regulatory reforms of particular countries/ regions that restrict the sale or clinical trials of Fc-fusion in that region. Also, upcoming alternatives for Fc-fusion proteins can pose to be restraining for the Fc-fusion market.
|On the basis of Application||
|On the basis of End-Users||
|On the basis of Region||
From the global perspective, North America accounts for the largest market share for Fc-fusion protein owing to the rising efficacy of Fc-fusion proteins therapy and adoption rate of advance Fc-fusion proteins. The high adoption rate of Fc-fusion proteins in North America probably will help the region to retain the position of the leading region in the forecast years.
However, other regions like Asia-Pacific, Middle East & Africa are expected to be probable markets in coming years. Across emerging markets, Asia Pacific and Latin America, the Fc-fusion proteins market is expected to have a strong growth in the forecast years. Due to the extensive awareness about the Fc-fusion proteins, these areas are most likely to be potential markets for Fc-fusion proteins.
Currently, the global Fc-fusion proteins market is highly competitive owing to the involvement of many established players. Some of the key players in the global Fc-fusion proteins market are
Astellas Pharma US, Regeneron, Amgen, Ligand Pharmaceuticals, Bristol-Myers Squibb, Viventia and Genzyme.